News >

CAR T-Cell Therapy Explored in Mantle Cell Lymphoma

Angelica Welch
Published: Thursday, Jun 07, 2018

Dr. Michael Wang
Michael Wang, MD,
Overcoming resistance to BTK inhibitors is the biggest clinical unmet need in the treatment of patients with mantle cell lymphoma (MCL), according to Michael Wang, MD. Patients who progress on treatment with ibrutinib (Imbruvica) and acalabrutinib (Calquence) are often incurable, challenging investigators to find a new avenue of treatment.

According to Wang, the results from ZUMA-2 will read out at the end of 2018.


  1. Wang M, Locke FL, Siddiqi T, et al. ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with relapsed/refractory mantle cell lymphoma. Ann Oncol. 2016;27(6). doi: 10.1093/annonc/mdw375.40.
  2. Locke FL, Neelapu SS, Bartlett NL, et al. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). In: Proceedings from the 2017 AACR Annual Meeting; April 1-5, 2017; Washington, DC. Abstract CT019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication